The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on July 17, 2025

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 pivotal trial is on track for topline …

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

KFSHRC Performs World’s First Robotic-Assisted BiVAD Implantation

KFSHRC Performs World’s First Robotic-Assisted BiVAD Implantation

RIYADH, Saudi Arabia, July 17, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first implantation of two artificial pumps for biventricular support (BiVAD-HMIII) using …

Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results

Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results

New York City, NY, July 17, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Peptides for Muscle Growth Are Dominating the 2025 Supplement Scene As the demand for clean, high-performance muscle-building solutions rises, oral legal peptides are taking the fitness …

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

WHO WHAT WHEN WHY Nuwellis, Inc. Termination of the REVERSE-HF clinical trial July 17, 2025 To redirect resources toward outpatient markets where scalable impact is highest.   MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced …

Repligen to Report Second Quarter 2025 Financial Results

Repligen to Report Second Quarter 2025 Financial Results

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market …

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

DURHAM, N.C., July 17, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies (“Palantir”) to automate and streamline the …

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet …

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces …

Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink

Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink

BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch of Mock One, a new line of non- …

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

Current Board member John Duke to succeed Jim Green as President …

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the …

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge Health by I-Mab …

Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call

Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 7, 2025, to be followed by a …

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss …

Teleflex Announces Second Quarter 2025 Earnings Conference Call Information

Teleflex Announces Second Quarter 2025 Earnings Conference Call Information

WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To …

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron - FY25 global sales exceed projection, up 49% on prior year

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year …

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in …

EAACI-Führung blickt auf rekordverdächtigen Kongress 2025 zurück: Ein entscheidender Moment für Allergologie und Immunologie

EAACI-Führung blickt auf rekordverdächtigen Kongress 2025 zurück: Ein entscheidender Moment für Allergologie und Immunologie

ZÜRICH, July 17, 2025 (GLOBE NEWSWIRE) -- Mit über 7.600 Teilnehmern hat der EAACI-Kongress 2025 nicht nur aufgrund seiner Größe Schlagzeilen gemacht, sondern auch aufgrund der eindringlichen Botschaft seiner Führungskräfte. Nun, einen Monat nach Abschluss …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service